These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22726098)

  • 1. von Willebrand disease biology.
    Blombäck M; Eikenboom J; Lane D; Denis C; Lillicrap D
    Haemophilia; 2012 Jul; 18 Suppl 4():141-7. PubMed ID: 22726098
    [No Abstract]   [Full Text] [Related]  

  • 2. Erik von Willebrand.
    Berntorp E
    Thromb Res; 2007; 120 Suppl 1():S3-4. PubMed ID: 17512040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand disease and Weibel-Palade bodies.
    Wang JW; Eikenboom J
    Hamostaseologie; 2010 Aug; 30(3):150-5. PubMed ID: 20680229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased susceptibility of von Willebrand factor to proteolysis by ADAMTS13: should the multimer profile be normal or type 2A?
    Bowen DJ
    Blood; 2004 Apr; 103(8):3246. PubMed ID: 15070714
    [No Abstract]   [Full Text] [Related]  

  • 6. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
    Budde U; Schneppenheim R
    Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAMTS-13 activity in von Willebrand disease.
    Perutelli P; Amato S; Molinari AC
    Thromb Res; 2006; 117(6):685-8. PubMed ID: 15993931
    [No Abstract]   [Full Text] [Related]  

  • 8. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain.
    Casonato A; De Marco L; Gallinaro L; Sztukowska M; Mazzuccato M; Battiston M; Pagnan A; Ruggeri ZM
    Thromb Haemost; 2007 Apr; 97(4):527-33. PubMed ID: 17393013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2M von Willebrand disease: a variant of type 2A?
    Batlle J; Pérez-Rodríguez A; Franqueira MD; López-Fernández MF
    J Thromb Haemost; 2008 Feb; 6(2):388-90. PubMed ID: 18036186
    [No Abstract]   [Full Text] [Related]  

  • 10. Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor.
    Daidone V; Barbon G; Pontara E; Cattini GM; Gallinaro L; Zampese E; Pizzo P; Casonato A
    Thromb Haemost; 2014 Dec; 112(6):1159-66. PubMed ID: 25230768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor.
    Casonato A; Pontara E; Battiston M; Morpurgo M; Cattini MG; Casarin E; Saga G; Daidone V; De Marco L
    Thromb Haemost; 2013 Jun; 109(6):999-1006. PubMed ID: 23446343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical implications of ADAMTS13 function: the perspectives of haemostaseologists.
    Rangarajan S; Kessler C; Aledort L
    Thromb Res; 2013 Oct; 132(4):403-7. PubMed ID: 24050828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biogenesis of Weibel-Palade bodies.
    Hannah MJ; Williams R; Kaur J; Hewlett LJ; Cutler DF
    Semin Cell Dev Biol; 2002 Aug; 13(4):313-24. PubMed ID: 12243731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 A (group II) von Willebrand disease mutations increase the susceptibility of VWF to ADAMTS-13.
    Tsai HM
    J Thromb Haemost; 2004 Nov; 2(11):2057. PubMed ID: 15550049
    [No Abstract]   [Full Text] [Related]  

  • 15. C1584 in von Willebrand factor is necessary for enhanced proteolysis by ADAMTS13 in vitro.
    Keeney S; Grundy P; Collins PW; Bowen DJ
    Haemophilia; 2007 Jul; 13(4):405-8. PubMed ID: 17610557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size.
    Jin SY; Skipwith CG; Shang D; Zheng XL
    J Thromb Haemost; 2009 Oct; 7(10):1749-52. PubMed ID: 19682236
    [No Abstract]   [Full Text] [Related]  

  • 17. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.
    Hilbert L; Federici AB; Baronciani L; Dallagiovanna S; Mazurier C
    Haematologica; 2004 Sep; 89(9):1128-33. PubMed ID: 15377475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand's disease.
    Hoyer LW
    Prog Hemost Thromb; 1976; 3():231-87. PubMed ID: 781732
    [No Abstract]   [Full Text] [Related]  

  • 20. ABO blood group and von Willebrand factor: biological implications.
    Franchini M; Crestani S; Frattini F; Sissa C; Bonfanti C
    Clin Chem Lab Med; 2014 Sep; 52(9):1273-6. PubMed ID: 24945431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.